Lexi Ding

Lexi Ding

Auto-generated profile, based on publicly available information

Lexi Ding

Department of Ophthalmology, Xiangya Hospital, Central South University, Changsha, 410008, China

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
YHYang Hu
Yang Hu
YCYing Chen
Ying Chen
LDLexi Ding
Lexi Ding
XHXuemin He
Xuemin He
YTYusuke Takahashi
Yusuke Takahashi
Jian-xing MaJian-xing Ma
Jian-xing Ma
Significance: This study investigated the expression and function of peroxisome proliferator-activated receptor alpha (PPARα) in the retina and its role in diabetic retinopathy. In both type 1 and type 2 diabetes models, expression of PPARα was significantly down-regulated in the retina. PPARα knockout exacerbated diabetes-induced retinal vascular leakage and retinal inflammation, while over-expression of PPARα in the retina of diabetic rats significantly alleviated diabetic retinopathy. This study reveals that PPARα has an anti-inflammatory function in the retina. These findings also suggest that diabetes-induced down-regulation of PPARα plays an important role in diabetic retinopathy and represents a novel therapeutic target for diabetic retinopathy.

1 October 2014 in The American Journal of Pathology
Verified
Journal Article
Open access
LDLexi Ding
Lexi Ding
RCRui Cheng
Rui Cheng
YHYang Hu
Yang Hu
YTYusuke Takahashi
Yusuke Takahashi
AJAlicia Jenkins
Alicia Jenkins
Jian-xing MaJian-xing Ma
Jian-xing Ma
Pericyte degeneration is an early event in diabetic retinopathy and plays an important role in progression of diabetic retinopathy. Clinical studies have shown that fenofibrate, a peroxisome proliferator-activated receptor α (PPARα) agonist, has robust therapeutic effects on diabetic retinopathy in type 2 diabetic patients. We evaluated the protective effect of PPARα against pericyte loss in diabetic retinopathy. In streptozotocin-induced diabetic mice, fenofibrate treatment significantly ameliorated retinal acellular capillary formation and pericyte loss. In contrast, PPARα(-/-) mice with diabetes developed more severe retinal acellular capillary formation and pericyte dropout, compared with diabetic wild-type mice. Furthermore, PPARα knockout abolished the protective effect of fenofibrate against diabetes-induced retinal pericyte loss. In cultured primary human retinal capillary pericytes, activation and expression of PPARα both significantly reduced oxidative stress-induced apoptosis, decreased reactive oxygen species production, and down-regulated NAD(P)H oxidase 4 expression through blockade of NF-κB activation. Furthermore, activation and expression of PPARα both attenuated the oxidant-induced suppression of mitochondrial O2 consumption in human retinal capillary pericytes. Primary retinal pericytes from PPARα(-/-) mice displayed more apoptosis, compared with those from wild-type mice under the same oxidative stress. These findings identified a protective effect of PPARα on retinal pericytes, a novel function of endogenous PPARα in the retina.

1 July 2014 in Investigative Ophthalmology & Visual Science
Verified
Journal Article
Open access
PDF file
EMElizabeth Moran
Elizabeth Moran
LDLexi Ding
Lexi Ding
ZWZhongxiao Wang
Zhongxiao Wang
RCRui Cheng
Rui Cheng
QCQian Chen
Qian Chen
Jian-xing MaJian-xing Ma
Jian-xing Ma
Purpose.: Previous studies have demonstrated that peroxisome proliferator-activated receptor-alpha (PPARα) agonists have therapeutic effects in diabetic retinopathy, although the mechanism of action remains incompletely understood. The purpose of this study was to evaluate PPARα's protective effects in the ischemic retina, and to delineate its molecular mechanism of action. Methods.: For the oxygen-induced retinopathy (OIR) model, wild-type (WT), and PPARα knockout (PPARα−/−) mice were exposed to 75% O2 from postnatal day 7 (P7) to P12 and treated with the PPARα agonist fenofibric acid (Feno-FA) from P12 to P16. At P17, the effects of Feno-FA on retinal glial fibrillary acidic protein (GFAP) expression, apoptotic DNA cleavage, and TUNEL labeling were analyzed. Cultured retinal cells were exposed to CoCl2 to induce hypoxia, and TUNEL staining and 5-(and-6)-chloromethyl-2′,7′-dichlorodihydrofluorescein dye were used to measure apoptosis and reactive oxygen species (ROS) generation. Western blotting was used to measure GFAP levels and cell signaling. Results.: Feno-FA decreased retinal apoptosis and oxidative stress in WT but not PPARα−/− OIR mice. Peroxisome proliferator-activated receptor-alpha knockout OIR mice showed increased retinal cell death and glial activation in comparison to WT OIR mice. Feno-FA treatment and PPARα overexpression protected cultured retinal cells from hypoxic cell death and decreased ROS levels. Nuclear hypoxia-inducible factor-α (HIF-1α) and nicotine adenine dinucleotide phosphate oxidase-4 (Nox 4) were increased in OIR retinas and downregulated by Feno-FA in WT but not in PPARα−/− mice. Conclusions.: Peroxisome proliferator-activated receptor-alpha has a potent antiapoptotic effect in the ischemic retina. This protective effect may be mediated in part through downregulation of HIF-1α/Nox 4 and consequently alleviation of oxidative stress.

19 August 2016 in Diabetes
Verified
Journal Article
Open access
PDF file
RCRui Cheng
Rui Cheng
LDLexi Ding
Lexi Ding
XHXuemin He
Xuemin He
YTYusuke Takahashi
Yusuke Takahashi
Jian-xing MaJian-xing Ma
Jian-xing Ma
Peroxisome proliferator–activated receptor-α (PPARα) displays renoprotective effects with an unclear mechanism. Aberrant activation of the canonical Wnt pathway plays a key role in renal fibrosis. Renal levels of PPARα were downregulated in both type 1 and type 2 diabetes models. The PPARα agonist fenofibrate and overexpression of PPARα both attenuated the expression of fibrotic factors, and suppressed high glucose–induced or Wnt3a-induced Wnt signaling in renal cells. Fenofibrate inhibited Wnt signaling in the kidney of diabetic rats. A more renal prominent activation of Wnt signaling was detected both in PPARα−/− mice with diabetes or obstructive nephropathy and in PPARα−/− tubular cells treated with Wnt3a. PPARα did not block the transcriptional activity of β-catenin induced by a constitutively active mutant of lipoprotein receptor–related protein 6 (LRP6) or β-catenin. LRP6 stability was decreased by overexpression of PPARα and increased in PPARα−/− tubular cells, suggesting that PPARα interacts with Wnt signaling at the Wnt coreceptor level. 4-Hydroxynonenal–induced reactive oxygen species production, which resulted in LRP6 stability, was suppressed by overexpression of PPARα and dramatically enhanced in PPARα−/− tubular cells. Diabetic PPARα−/− mice showed more prominent NADPH oxidase-4 overexpression compared with diabetic wild-type mice, suggesting that the inhibitory effect of PPARα on Wnt signaling may be ascribed to its antioxidant activity. These observations identified a novel interaction between PPARα and the Wnt pathway, which is responsible, at least partially, for the therapeutic effects of fenofibrate on diabetic nephropathy.

1 June 2019 in European Journal of Pharmacology
Verified
Journal Article
Closed access
JPJing-Jie Peng
Jing-Jie Peng
SXSiqi Xiong
Siqi Xiong
LDLe-Xi Ding
Le-Xi Ding
JPJun Peng
Jun Peng
XXXiaobo Xia
Xiaobo Xia

4 February 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
EPElizabeth A Pearsall
Elizabeth A Pearsall
RCRui Cheng
Rui Cheng
SMSatoshi Matsuzaki
Satoshi Matsuzaki
KZKelu Zhou
Kelu Zhou
LDLexi Ding
Lexi Ding
Jian-xing MaJian-xing Ma
Jian-xing Ma
Diabetic retinopathy (DR) is a common neurovascular complication of type 1 diabetes. Current therapeutics target neovascularization characteristic of end-stage disease, but are associated with significant adverse effects. Targeting early events of DR such as neurodegeneration may lead to safer and more effective approaches to treatment. Two independent prospective clinical trials unexpectedly identified that the PPARα agonist fenofibrate had unprecedented therapeutic effects in DR, but gave little insight into the physiological and molecular mechanisms of action. The objective of the present study was to evaluate potential neuroprotective effects of PPARα in DR, and subsequently to identify the responsible mechanism of action. Here we reveal that activation of PPARα had a robust protective effect on retinal function as shown by Optokinetic tracking in a rat model of type 1 diabetes, and also decreased retinal cell death, as demonstrated by a DNA fragmentation ELISA. Further, PPARα ablation exacerbated diabetes-induced decline of visual function as demonstrated by ERG analysis. We further found that PPARα improved mitochondrial efficiency in DR, and decreased ROS production and cell death in cultured retinal neurons. Oxidative stress biomarkers were elevated in diabetic Pparα-/- mice, suggesting increased oxidative stress. Mitochondrially mediated apoptosis and oxidative stress secondary to mitochondrial dysfunction contribute to neurodegeneration in DR. Taken together, these findings identify a robust neuroprotective effect for PPARα in DR, which may be due to improved mitochondrial function and subsequent alleviation of energetic deficits, oxidative stress and mitochondrially mediated apoptosis.